Jack C R, Nichols D A, Sharbrough F W, Marsh W R, Petersen R C, Hinkeldey N S, Ivnik R J, Cascino G D, Ilstrup D M
Department of Diagnostic Radiology, Mayo Clinic.
Mayo Clin Proc. 1989 Aug;64(8):965-75. doi: 10.1016/s0025-6196(12)61225-7.
The carotid Amytal test (Wada test) was introduced, in 1948 by Wada, to localize speech function before temporal lobectomy in patients with medically refractory epilepsy, and it remains the standard for that purpose. The same test has also been used since 1962 to evaluate memory function; however, the adequacy of the test in this application has been viewed with increasing skepticism in recent years. Therefore, we developed an alternative to the Wada test. It consists of selective injection of Amytal into the posterior cerebral artery (PCA). This PCA Amytal test is designed to test only memory function (not language). We present several anatomic and functional reasons why this approach should be superior to the Wada test for this purpose. We also present preliminary data in support of this hypothesis. To date, we have had successful results of the PCA Amytal test in 38 of 45 patients (84%), and one major complication has occurred (2%).
1948年,和田(Wada)引入了颈动脉阿米妥试验(Wada试验),用于在药物难治性癫痫患者进行颞叶切除术前定位语言功能,并且它仍然是该目的的标准方法。自1962年以来,同样的试验也被用于评估记忆功能;然而,近年来人们对该试验在这一应用中的充分性越来越持怀疑态度。因此,我们开发了一种替代Wada试验的方法。它包括将阿米妥选择性注入大脑后动脉(PCA)。这种PCA阿米妥试验仅用于测试记忆功能(而非语言功能)。我们提出了几个解剖学和功能方面的原因,说明为什么这种方法在此目的上应优于Wada试验。我们还提供了支持这一假设的初步数据。迄今为止,我们对45例患者中的38例(84%)进行PCA阿米妥试验获得了成功结果,并且发生了1例严重并发症(2%)。